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Summary We have detected somatostatin receptors (SSR) by autoradiography in 3/4 established small cell
lung cancer (SCLC) cell lines but not in two non-SCLC cell lines. The growth of 1/3 SSR positive SCLC cell
lines was significantly inhibited by the long-acting somatostatin analogue octreotide (SMS 201-995, Sando-
statin) 10-9M. We treated 20 SCLC patients with octreotide 250 gg three times daily for I week pre-
chemotherapy (six patients) or at relapse after chemotherapy (14). Octreotide was well tolerated, and serum
insulin-like growth factor-I levels were suppressed to 62±7% of pre-treatment levels. However there was no
evidence of anti-tumour activity measured by tumour bulk or serum levels of neuron-specific enolase. In one
patient metastatic skin nodules were shown to be SSR positive before and at the end of 2 weeks octreotide.
Despite this the patient had progressive disease, and tumour cells obtained by fine needle aspirate before and
after treatment showed no growth inhibition when cultured with octreotide immediately or following establish-
ment as a cell line. In summary we saw little correlation between SSR expression and growth inhibition by
octreotide, either in vitro or clinically.
Somatostatins are a family of 14- and 28-residue neuropep-
tides which regulate peptide secretion from the pituitary, gut
and pancreas (Bloom & Polak, 1987; Frohman & Krieger,
1987). Somatostatin receptors (SSR) are expressed by these
so-called 'SS target tissues', and by tumours arising from
them including pituitary adenomas and pancreatic insulin-
omas (Reubi et al., 1982; 1984). Natural SS-14 is of limited
therapeutic use here because of its short plasma half-life
(3 min) and diverse action (Moreau & DeFeudis, 1987;
Schally, 1988). Systematic structure/activity studies have led
to the development of potent octapeptide SS analogues with
prolonged and selective activity. One of these, octreotide
(SMS 201-995, Sandostatin) has pharmacological effects in
vivo for up to 9 h and is 45-70 times more potent than SS-14
at inhibiting growth hormone release (Plewe et al., 1987;
Schally, 1988). In patients with acromegaly, carcinoid synd-
rome, insulinomas and other gastroenteropancreatic tumours,
octreotide produces clinical improvement in parallel with
suppression of inappropriate peptide secretion, and in
some cases reduction in tumour bulk (Kraenzlin et al., 1985;
Wood et al., 1985; Kvols et al., 1986; Lamberts et al., 1987;
Comi, 1989; Maton, 1989). Octreotide and other octapeptide
SS analogues have also shown experimental evidence of anti-
proliferative activity in some common solid tumours, includ-
ing cancers of the breast, exocrine pancreas, colon and
prostate (Setyono-Han et al., 1987; Schally, 1988; Parmar et
al., 1989; Weber et al., 1989). Growth inhibition here could
be mediated directly, via SSR which have been detected on
breast, pancreas and prostate cancers (Reubi et al., 1987;
Setyono-Han et al., 1987; Srkalovic et al., 1990), or indirectly
via suppression of local or circulating levels ofgrowth factors
(Schally, 1988).
There is some evidence that SS may play a role in growth
regulation of small cell lung cancer (SCLC). SS-like immuno-
reactivity has been detected in SCLC cells (Sorensen et al.,
1981). SSR are expressed in SCLC tumours and cultured
cells but not by non-SCLC (Taylor et al., 1988a; Reubi et al.,
1990). The octapeptide SS analogue somatuline (BIM-
23014C) has been shown to inhibit the growth of SCLC
xenografts in immune-deprived mice (Taylor et al., 1988b;
Bogden et al., 1990).
We have assessed the in vitro response of SCLC and
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non-SCLC cells to octreotide, correlating SSR expression
with effects on growth and secretion of insulin-like growth
factor-I (IGF-I), an autocrine growth factor for lung cancer
cells (Minuto et al., 1988; Macaulay et al., 1988a; 1990).
Results from these in vitro studies described below encou-
raged us to proceed to a clinical study, based on the fact that
octreotide is a safe and well-tolerated drug (Parmar et al.,
1989; Reubi et al., 1990). The main part of this study involv-
ed patients who had relapsed off-treatment after initial res-
ponse to conventional chemotherapy. In addition we tried to
assess octreotide in previously untreated patients, over a 7
day period during admission for staging investigations prior
to conventional chemotherapy. In this latter group we hoped
that serum neuron-specific enolase, a tumour marker for
SCLC (Carney et al., 1982), would be sufficiently sensitive to
permit evaluation of response especially in the group treated
for 7 days before chemotherapy. We also measured circu-
lating levels of IGF-I. We have shown that serum IGF-I
levels do not correlate with tumour bulk in patients with
SCLC (Macaulay et al., 1988b) and we used this parameter
not as a tumour marker but rather as a measure of the
endocrine effects of octreotide, as reported in acromegaly
(Lamberts et al., 1988).
Patients and methods
Human lung cancer cells
We obtained SCLC cell lines HC12 and HX149 from Dr G.
Duchesne, Institute of Cancer Research, Surrey, NCI-H69
from Dr D. Carney, Mater Hospital, Dublin and non-SCLC
cell lines NCI-H23 and -H226 from Dr A. Gazdar, National
Cancer Institute, Bethesda, Maryland. SCLC cell line ICR-
SC17 was established by us. Cell lines were characterised as
previously described (Carney et al., 1985; Duchesne et al.,
1987; Macaulay et al., 1987) and were cultured in RPMI
1640 medium with 5% foetal calf serum (FCS). For estab-
lishment of xenografts, 2-5 x 106 cells were innoculated sub-
cutaneously into the flanks of female athymic (nu/nu) mice.
Fresh tumour cells were obtained by fine needle aspiration of
metastatic skin nodules in a patient with SCLC. The cells
were taken into 1 ml unsupplemented RPMI medium, and a
drop of the cell suspension was smeared on a slide and
stained with Giemsa to confirm SCLC morphology. Half the
remaining cell suspension was used in a 3Hthymidine incor-
poration assay (see below). Half was cultured in RPMI plus
5% FCS, and became established as cell line ICR-SC132.
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Patients and treatment
Twenty patients with histologically proven SCLC were enter-
ed into this study. Six patients were previously untreated,
including three men and three women with a median age of
59.5 years (56-65 years). One patient had limited disease
(LD, confined to one hemithorax and ipsilateral supracla-
vicular nodes) and five had extensive disease (ED). Fourteen
patients were recruited on relapse following chemotherapy
with ACE (Adriamycin, cyclophosphamide, etoposide) or
MVC (methotrexate, vinblastine, carboplatin). They included
11 men and three women with a median age of 61.5 years
(44-71). At presentation five had been staged as LD, and
nine as ED. Before starting octreotide all patients were
assessed by clinical examination, chest X-ray (CXR), full
blood count (FBC) and biochemistry including liver function
tests (LFTs). Serum was stored at -70C for IGF-I and
NSE assay. Other investigations (abdominal ultrasound scan,
isotope bone scan, CT brain scan) were performed if clinic-
ally indicated.
Octreotide was administered subcutaneously: 50fig 8-hour-
ly for 24 h, 100 jg 8-hourly for 24 h, then 250 lug 8-hourly. In
previously treated patients octreotide was continued to
disease progression or development of unacceptable toxicity.
Gastrointestinal side-effect were treated with codeine phos-
phate 30-60 mg 4-hourly. If side-effects persisted, octreotide
was given at a lower dose, and if necessary was discontinued.
Staging investigations were repeated after 7 days in the group
treated at presentation, and every 1-2 weeks in relapsed
patients. At these intervals serum samples were obtained for
NSE and IGF-I assays. Additional samples were obtained
every 2 days from patients undergoing in-patient treatment
before chemotherapy. Response was assessed by standard
criteria (Miller et al., 1981) and by serial serum levels of NSE
and IGF-I. Side effects were graded as mild (grade 1), moder-
ate (2), or severe (3).
Growth assays
Octreotide was provided by Dr P. Marbach, Sandoz, Basle. It
was dissolved in sodium acetate buffer pH 6 with 0.1% bovine
serum albumin (SMS buffer). 3H thymidine incorporation
assays were performed in sterile 96-well microtitre plates
(Macaulay et al., 1988a). Single cell suspensions were pre-
paring by syringing (SCLC) or trypsinisation (non-SCLC).
Assays used cultured cells (6 x 103/well) or fresh nucleated
cells (105/well) obtained by fine needle aspirate of metastatic
skin nodules. The cells were cultured in unsupplemented
RMPI in the presence of octreotide 10-11-10-6M. Control
wells received SMS buffer without octreotide. After 46 h incu-
bation (37°C, 5% C02) the cells were labelled with 3H thymi-
dine (Amersham) 0.4gCiwell, and after 24 h they were
harvested and counted as previously described (Macaulay et
al., 1988a). For growth curves, cells were cultured in unsupple-
mented RPMI, RPMI plus TIS transferrin 100;gml1l or
RPMI plus 5% FCS. Every 2-3 days, viable cell numbers
were counted on a haemocytometer by trypan blue exclusion.
After 2-4 days, when cell numbers were level or rising, cul-
tures were treated with SMS buffer (controls) or octreotide
10-' or 10-6M. Samples of unconditioned and conditioned
medium were stored at -20°C for later IGF-I assay. Growth
assays on fresh tumour cells were performed once. Experi-
ments on established cell lines were repeated at least twice, and
the results ofrepresentative single experiments are given as the
mean ± s.e.m. of triplicate estimations. Statistical assessment
of differences between control and treatment groups used one-
way analysis of variance and Dunnett's test (Zar, 1984).
Somatostatin receptors (SSR)
Cultures of human lung cancer cells in exponential growth
phase were prepared by a method used to study epidermal
growth factor receptor (Professor B. Gusterson, personal
communication). Adherent monolayers (NCI-H23 and -H226)
were detached by scraping into the medium, the cultures were
centrifuged (2,000 r.p.m., 7 min) and the cell pellet was
embedded in Tissue Tek OCT compound embedding medium
(Ames, Indiana). Fresh tumour tissue was obtained by biopsy
of subcutaneous nodules from one patient with SCLC before
and at the end of octreotide treatment, and from mice bear-
ing xenografts of HC12, HX149 and NCI-H226 on first
passage in vivo. Cell pellets and tumours were snap frozen in
liquid nitrogen and stored at - 70°C. SSR were measured by
autoradiography (ARG) on cryostat sections as previously
described (Reubi et al., 1990).
Radioimmunoassaysfor NSE and IGF-I
Serum NSE was measured on duplicate samples by radio-
immunoassay (Pharmacia Ltd, Milton Keynes, UK). For
IGF-I assay, unconditioned and conditioned media were cen-
trifuged (1,000 r.p.m., 5 min), lyophilised, and reconstituted
in distilled water at one tenth the original volume. Samples
of medium and patients' serum underwent acid ethanol ex-
traction with 2 N hydrochloric acid: absolute ethanol, 1:7 and
were neutralised with Tris buffer. Duplicate aliquots were
assayed using anti-IGF-I monoclonal antibody BPL-M23 as
previously described (Teale & Marks, 1986; 1990; Macaulay
et al., 1990). Analysis of variance and Dunnett's test were
used to assess the significance of differences in NSE and
IGF-I levels before and during octreotide therapy.
Results
Establishedlung cancer cell lines
3H thymidine incorporation assays were performed on
HX149 and HCl2, to select octreotide doses for further
study. Octreotide caused significant inhibition of 3H thymi-
dine incorporation at I0- M in HX149 (63 ± 1% control,
P<0.05; see Figure 1) and at 10-6 M in HC12 (87 ± 2%,
P<0.05). We then tested the effect of octreotide 10-' and
10-6 M on growth and IGF-I secretion by lung cancer cells in
longer term culture. In HX149 growing in RPMI plus 5%
FCS, cell numbers were lower in octreotide-treated cultures
(Figure 2). Inhibition was greatest in the presence of octreo-
tide 10-9 M, but the effects of both 10-' and 10-6 M were
significantly lower than control on days 9-16 (P<0.01). As
we previously reported, HX149 secretes low levels of IGF-I,
around 0.5 ngml-'. It was not possible to discern any oct-
reotide-induced alteration in IGF-I secretion in the presence
of 5% FCS, which provides around 2-5 ngml-I IGF-I
(Macaulay et al., 1988a; 1990). We attempted to circumvent
this problem by performing experiments in unsupplemented
RPMI or RPMI plus TIS, but HX149 did not grow satisfac-
torily without serum. Octreotide 10-' or 10-6 Mhad no effect
on growth or IGF-I secretion by HC12, NCI-H69, ICR-
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Figure 1 Effect of octreotide on 3H thymidine incorporation by
SCLC cell line HX149.






Figure 2 Effect of octreotide 1O-9M (A) or 10-6 M (A) on
SCLC cell line HX149 in RPMI plus 5% FCS.
Receptor autoradiography of xenograft tissue showed
weakly positive SSR expression in HX149 and no detectable
SSR in HC12 or NCI-H226. SSR were also detectable in cell
pellets of NCI-H69, HX149 and ICR-SC17, but not in
HC12, NCI-H23 or -H226. In NCI-H69 SSR were homogen-
ously distributed at high density, whereas SSR expression by
HX149 and ICR-SC17 was weak and patchy.
Clinical study in patients with SCLC
The six previously untreated patients with SCLC were treated
with octreotide for a median 7 days (range 1-11 days). The
14 patients with slow-tempo relapse after chemotherapy
received median 17 days treatment (2-104 days). Octreotide
was administered on an out-patient basis by the patients
themselves (seven cases), a relative (three), or district nurses
(one, treated with 375 jig bd). Four in-patients received injec-
tions from ward nurses.
Five of six previously untreated patients had no change in
tumour bulk during the week of therapy. One had progres-
sive disease (PD) in mediastinal lymph nodes, with the
development of stridor. Two of 14 relapsed patients had
stable disease (SD) accompanied by relief of respiratory
symptoms, and were able to continue octreotide for 8 and 15
weeks. Of 12 patients treated for less then 1 month, one
stopped treatment after 2 days and was not evaluable for
response, and the others had progressive disease (see Table
I). One patient with multiple metastatic skin nodules con-
sented to further studies on the effect of octreotide on
tumour cell growth and SSR expression (see below).
Serum was obtained for NSE and IGF-I assay in all
patients before starting octreotide and serial samples were
available in 18. Five of six previously untreated patients had
high baseline NSE levels (>12ngml-') and of four with
serial measurements one remained high, two fell slightly (39.5
to 29.5 and 14 to I0ngml['; P<0.05 in each case) and one
rose significantly from 72 (pre-octreotide) to 200 (on treat-
ment; P<0.05) to 78 (end of treatment). An early 'surge' in
NSE has been previously noted in response to chemotherapy,
where it may represent rapid destruction of NSE-producing
cells (Nou et al., 1990). Thirteen of 14 relapsed patients had
high pretreatment serum NSE levels. Of 12 with serial
measurements, NSE levels fell from 28 to 9 ngml1l in one
case (P<0.01). In six patients there was no statistically
Table I Clinical response to octreotide in 20 patients with SCLC
CR/PR SD PD NE Total
significant alteration in NSE levels although all had PD
clinically. Five patients had a significant rise (P<0.01) in
serum NSE while on octreotide, including four with clinical
PD and one who had stable disease until the end of 15 weeks
octreotide.
Pre-octreotide serum IGF-I levels were normal in 17/20
patients. Low levels (<0.2 u ml-1) in three cases were prob-
ably related to abnormal liver function (D'Ercole et al.,
1984). Serum IGF-I was suppressed during treatment with
octreotide in 15 of 18 patients who had serial measurements.
Serum IGF-I levels fell in all five previously-untreated
patients where serial samples were obtained (P<0.05 in two
cases, P<0.01 in three). This includes one patient in whom
IGF-I levels on octreotide were, at 0.07-0.13 uml -, below
the normal range (>0.2 u ml-'). Of 13 relapsed patients
with serial measurements, IGF levels were unchanged in four
and fell in eight (P<0.05 in two cases, P<0.01 in six). One
patient had a significant rise in serum IGF-I (0.22-0.56u
ml-', P<0.01) possibly related to an improvement in nutri-
tional status accompanied by symptomatic benefit and stable
disease clinically. Overall the change in IGF-I, expressed as
the lowest level on octreotide as a per cent of the pre-
treatment value, was median 53%, mean 62 ± 7% (range
23-150%).
Octreotide was well tolerated by most patients. Details of
symptomatic toxicity are given in Table II. Ten patients
experienced local pain at the site of administration. In one
this led to cessation of therapy, but in the rest it was
ameliorated by giving the injection slowly. Eleven patients
had gastrointestinal side-effects which were generally mild,
but which necessitated dose reduction to 100 Lg tds in two
cases and cessation of therapy in one case. One patient
accidentally administered 1,000 ig instead of 100lig octreo-
tide on the second day of therapy. She experienced vomiting
(grade 2) and 12 h of severe (grade 3) abdominal cramps and
diarrhoea. These symptoms settled within 12-24h, and she
was able to continue treatment at 250fig tds for 8 weeks.
These were no treatment-related changes in FBC or LFTs.
Four of six previously untreated patients completed the
planned 7 days of octreotide therapy. Treatment was discon-
tinued early in two cases, one for toxicity and the other for
PD. All six patients went on to receive combination chemo-
therapy in a randomised trial comparing ACE with MVC.
Five of the six responded to first-line chemotherapy, and all
responded to first or second-line chemotherapy. This group
had a median survival of 36 weeks (range 20-51) from the
start of treatment. Octreotide was discontinued in one
relapsed patients because of toxicity (local pain), and in the
remaining 13 because of PD. From the start of octreotide
therapy this group had a median survival of only 13 weeks
(3-50).
Experimental studies in onepatient with relapsed SCLC
A patient with SCLC (LD), inappropriate antidiuretic hor-
mone secretion, Lambert-Eaton myasthenic syndrome and
autonomic neuropathy who had relapsed after ACE chemo-
therapy with metastatic skin/subcutaneous nodules, consent-
ed to nodule biopsy and aspiration before and 2 weeks after
starting octreotide. During this period his tumour progressed.
Changes in serum NSE and IGF-I are shown in Figure 3.
Table II Side-effects ofoctreotide
Grade
Symptom 0 1 2 3
Local pain 10 7 1 2
Local erythema 17 3 0 0
Anorexia 18 1 1 0
Nausea/vomiting 18 0 2 0
Abdominal bloating/cramps 13 4 2 1
Diarrhoea 10 5 4 1
The table gives numbers of patients experiencing each symptom;
worst grade at any time during treatment.
Previously untreated 0 0 1 5 6
Relapsed after chemotherapy 0 2 11 1 14
CR -complete response; PR -partial response; SD - stable disease;
PD - progressive disease; NE - not evaluable.
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Figure 3 Effect of treatment with octreotide 250 1tg tds on serum
levels of NSE (0) and IGF-I (A) in patient with relapsed SCLC.
Normal ranges: NSE<12ngml-', IGF-I 0.2-1.2umlL'.
The pre-octreotide skin nodule biopsy showed metastatic
SCLC which expressed detectable SSR by ARG. Fine needle
aspiration of another skin lesion yielded fresh nucleated cells
of which 85% had typical SCLC morphology and the rest
were mature lymphocytes. Half the cells were incubated in
unsupplemented RPMI with octreotide 10-11-106M which
had no effect on 3H thymidine incorporation. The remaining
cells were cultured in RPMI plus 5% FCS and grew as
floating clusters, becoming established as SCLC cell line
ICR-SC132. After approximately 15 passages in vitro cultures
of ICR-SC132 in RPMI plus 5% FCS were grown in the
presence and absence of octreotide 10- or 106 M. There
was no evidence of growth inhibition or suppression of IGF-
I secretion. The post-octreotide skin nodule biopsy retained
typical features of SCLC and detectable SSR by ARG
(Figure 4). Fresh tumour cells obtained by fine needle aspira-
tion again showed no inhibition of 3H thymidine incorpora-
tion in the presence of octreotide 10- 10-6 M. This sample
did not establish as a cell line.
Discussion
In this study SSR were expressed by 3/4 established SCLC
cell lines but only 1/4 showed growth inhibition in response
to octreotide. This effect occurred in HX149 which expresses
SSR, albeit weakly. We observed maximum inhibition in the
presence of octreotide 1O-9 M, the concentration which is
achieved clinically following a single subcutaneous injection
of octreotide (del Pozo et al., 1986). The dose-response rela-
tionship in 3H-thymidine incorporation assay was similar to
the 'bell-shaped' curve seen in cultured breast cancer cells
(Setyono-Han et al., 1987). This could have important impli-
cations for the clinical assessment of SS analogues, since the
maximum tolerated dose may not necessarily have the great-
est antitumour effect. None of our SSR negative cell lines
were inhibited by octreotide, but neither was NCI-H69 which
expresses high levels of SSR. However growth of this cell line
was inhibited in vitro by two other octapeptide SS analogues,
somatuline (BIM-23014C) and RC-160 (Taylor et al., 1988b,
Dr A. Schally, personal communication). Somatuline also
inhibited the growth of NCI-H69 xenografts in vivo, espe-
cially when adminstered by perilesional infusion (Bogden et
al., 1990).
This clinical study was prompted by our in vitro data
together with reports from other groups demonstrating
experimental and clinical activity of SS analogues in NE
tumours including SCLC. In using a brief course of octreo-
tide in previously-untreated patients, we aimed to assess its
effects first-line without delaying conventional treatment.
None of six patients responded to octreotide but all subse-
Figure 4 Skin nodule biopsy in patients with relapsed SCLC
after 2 weeks treatment with octreotide. a, H&E, b, Total binding
of 125I Tyr-3-octreotide, c, Non-specific binding.
quently responded to combination chemotherapy. This is
important since it has been suggested that front-line treat-
ment with new agents may impair response to conventional
therapy given second-line (Cullen et al., 1987). We extended
the study to patients with slow-tempo relapse after chemo-
therapy, to assess more prolonged administration in terms of
effects on tumour bulk and feasibility as out-patient treat-
ment. Octreotide was generally well tolerated, but most
patients had PD within a few weeks and only two patients
were able to continue treatment for more than one month.
There was no evidence of clinical antitumour activity in any
patient, including one whose tumour was shown to express
SSR before and after treatment.
We hoped that serial measurements of serum NSE would
be sufficiently sensitive to detect small changes in tumour
bulk. However, short-term changes in NSE correlated poorly
with clinical status. Since this study began, others have ques-
tioned the value of serum NSE in monitoring response to
treatment, because in individual patients it adds little to
standard clinical staging (Carney & Teeling, 1988; Nou et al.,
1990).
Serum IGF-I levels fell in most patients, probably reflect-
ing suppression by octreotide of physiological (mainly
hepatic) IGF-I secretion, as occurs in diabetics (Plewe et al.,
1987). In acromegalics treated with octreotide, serum IGF-I
correlates well with levels of growth hormone and achieve-
ment of biochemical 'cure' (Lamberts et al., 1988). This
suggests that we had used an effective dose of octreotide, at
least in endocrine terms. A recently reported study of eight
patients with solid tumours (including cancers of the breast,
pancreas, colon, kidney and ovary) showed similar reduction
in circulating IGF-I levels on octreotide, although there were
no data on clinical response, and suggested that suppression
of serum IGF-I is in itself a promising approach to treatment
(Pollack et al., 1989). However it seems unlikely that we
could suppress secretion of IGF-I or other growth factors,
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to the point where their local tissue concentration would
limit neoplastic growth. Any growth inhibition seems more
likely to be mediated by a direct effect of SS analogues on
the tumour cells themselves.
In summary, although octreotide has documented anti-
tumour activity in other SSR positive NE tumours, we saw
little correlation between SSR expression and growth inhibi-
tion in SCLC, either in vitro or clinically. This may be
because the SSR detected on SCLC membranes do not medi-
ate a growth inhibitory response, as has been demonstrated
in meningiomas (Reubi et al., 1989). Alternatively we may
have used a suboptimal dose or schedule of octreotide. If the
dose-reponse curve is genuinely 'bell-shaped', as has been
suggested in breast cancer (Setyono-Han et al., 1987), the
maximum tolerated dose may not necessarily have the great-
est antiproliferative activity. Therefore it may be worth
assessing other doses/schedules of octreotide administration,
and other SS analogues reported to have pre-clinical activity
in SCLC. In particular, analogues of the RC series including
RC-160 have been shown to bind with higher affinity than
octreotide to SSR on human tumour membranes (Srkalovic
et al., 1990). The RC analogues, but not octreotide have also
been shown to stimulate dephosphorylation if the EGF
receptor in pancreatic cancer cells (Liebow et al., 1989). This
mechanism is not likely to be relevant in SCLC cells, which
lack EGF receptors (Reubi et al., 1990). Nevertheless, these
studies suggest that some SS analgoues might be superior to
others in terms of direct, receptor-mediated antitumour
activity.
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